Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;82(14):1489-1498.
doi: 10.1007/s40265-022-01791-3. Epub 2022 Oct 18.

Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis

Hannah A Blair  1
Affiliations
Review

Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis

Hannah A Blair. Drugs. 2022 Sep.

Abstract

Cabotegravir extended-release (ER) injectable suspension (Apretude™) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP). As an HIV-1 integrase strand transfer inhibitor, cabotegravir ER injectable suspension prevents DNA integration and inhibits HIV-1 replication. Its slow absorption and long elimination half-life permit infrequent dosing (1 month apart for two consecutive months, and every 2 months thereafter). Cabotegravir ER injectable suspension is indicated in the USA for PrEP to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing ≥ 35 kg who have a negative HIV-1 test prior to initiation. In clinical trials, cabotegravir ER injectable suspension had superior efficacy to oral daily emtricitabine/tenofovir disoproxil fumarate (DF) in preventing acquisition of HIV-1 in at-risk transgender women (TGW), cisgender men who have sex with men (MSM), and cisgender women. The drug was generally well tolerated, although further long-term data are needed to fully determine its safety. With its convenient, less-frequent dosing schedule and its long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP.

Plain language summary

Despite major advances in the prevention of HIV-1 transmission, there remain barriers to the widespread effective use of pre-exposure prophylaxis (PrEP). Approved daily oral PrEP requires people who do not have HIV-1 to take a pill every day to protect them from acquiring the infection. The availability of long-acting injectable PrEP that does not require daily dosing has the potential to improve uptake and adherence, particularly in high-risk individuals. Cabotegravir extended-release (ER) injectable suspension is the first long-acting injectable option to be approved for PrEP, and is given as an intramuscular injection as few as six times per year. Cabotegravir ER injectable suspension is more effective than daily oral emtricitabine/tenofovir disoproxil fumarate for preventing HIV-1 infection in adults who are at risk of sexually acquiring HIV-1. Cabotegravir ER injectable suspension is generally well tolerated and offers a convenient alternative to daily oral PrEP.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization. HIV/AIDS. 2021. https://www.who.int/news-room/fact-sheets/detail/hiv-aids . Accessed 20 Sep 2022.
    1. Pilgrim NA, Evans TM, Czarnogorski M. A layer plus approach to implementation research and collaboration for long-acting injectable pre-exposure prophylaxis for HIV prevention. Health Promot Pract. 2022. https://doi.org/10.1177/15248399211053584 . - DOI - PubMed
    1. Durham SH, Milam A, Waer D, et al. Cabotegravir: the first long-acting injectable for HIV preexposure prophylaxis. Ann Pharmacother. 2022. https://doi.org/10.1177/10600280221102532 . - DOI - PubMed
    1. Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020;15(1):19–26. - DOI - PubMed - PMC
    1. Flexner C. The future of long-acting agents for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17(4):192–8. - DOI - PubMed

LinkOut - more resources